pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,619 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT785Endpoints586BioPharma Dive224onclive165BioSpace60Fierce Biotech59raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Opinion: Florida is the first state to require EKGs for high school athletes. It’s a mistake
    “There are better ways for schools to protect student athletes,” writes Katherine Hofmann.
    STAT · 27d ago↗ source
  • STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
    The Trump administration's grand bargain with drugmakers isn't working out as planned.
    STAT · 27d ago↗ source
  • Opinion: Short-sighted new student loan caps elevate chiropractic care over critical health care professions
    “This administrative logic is hopelessly out of touch with the empirical reality of American health care,” writes David S. Shapiro.
    STAT · 27d ago↗ source
← prev
page 22 of 65
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
    Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
    STAT · 27d ago↗ source
  • STAT+: FDA’s top gene therapy regulator is leaving his role
    The departure of Vijay Kumar follows a broader leadership shakeup at the FDA.
    STAT · 27d ago↗ source
  • NEJM retracts pivotal data for Amgen's Tavneos
    Pivotal data for Amgen’s Tavneos have been retracted from the New England Journal of Medicine, creating another obstacle for the beleaguered autoimmune drug. Two academic authors requested the re…
    Endpoints · 27d ago↗ source
  • STAT+: AstraZeneca to pay $34 million to settle kickback charges filed by Texas attorney general
    AstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks to improperly influence prescriptions paid for by Texas Medicaid.
    STAT · 27d ago↗ source
  • STAT+: 26 states sue to block Medicaid work requirements
    States argue the rules will make it too hard for people to get the Medicaid coverage they're entitled too.
    STAT · 27d ago↗ source
  • John Reed on J&J’s R&D model, oncology deals and pipeline expansion potential
    John Reed has overseen the pipelines of three of the largest drugmakers since leaving Southern California's Sanford Burnham medical research institute 13 years ago, giving him unique insight into h…
    Endpoints · 27d ago↗ source
  • 5 takeaways from STAT’s investigation into microhospital operator Nutex Health
    Read the takeaways from STAT's investigation into Nutex, which used the No Surprises Act to fuel a stunning financial turnaround.
    STAT · 27d ago↗ source
  • EU lobby urges member states to improve Europe’s life sciences sector
    More than 200 biopharma investors and firms have signed an open letter calling for European governments to improve Europe’s life sciences sector. The Friday letter was addressed to EU member stat…
    Endpoints · 27d ago↗ source
  • STAT+: Unredacted comments from California hospital lawsuits show stunning admissions and a ‘forced’ McKinsey collaboration
    Who controls the Medicaid market, GLP-1 usage and pizza household costs, and more from Health Care Inc.
    STAT · 27d ago↗ source
  • STAT+: Longevity, wellness physicians named to panel advising FDA on peptides
    The panel will soon consider whether to relax restrictions on certain peptides.
    STAT · 27d ago↗ source
  • Zymeworks CEO on why the Theravance deal is value for money
    On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
    Endpoints · 27d ago↗ source
  • BioCryst ends internal discovery programs, will close Alabama research facility
    BioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal di…
    Endpoints · 28d ago↗ source
  • Evommune's lead drug fails in chronic hives, stock sinks
    Evommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin cond…
    Endpoints · 28d ago↗ source
  • Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone disease
    Plus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisit…
    Endpoints · 28d ago↗ source
  • Post-Hoc: China deals are pharma’s new tax inversions
    About a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...
    Endpoints · 28d ago↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 28d ago↗ source
  • De-Risking a Rare Disease Launch Starts with Precision
    Why traditional models fall short in rare disease commercialization—and what works instead.
    Fierce Biotech · 1mo ago↗ source
  • Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
    Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…
    Endpoints · 1mo ago↗ source
  • Opinion: Why the space in ‘health care’ matters
    When STAT polled our readers on ‘health care’ vs. ‘healthcare,’ about 60% of our readers voted for one word.
    STAT · 1mo ago↗ source
  • Opinion: STAT readers debate blue zones, open-access publishing fees, and more
    Keep those letters coming!
    STAT · 1mo ago↗ source
  • Endpoints News History: 10 Years, Bootstrap to FT
    Ten years of Endpoints News: no investors, a 50/50 split, profitable from day one. Co-founders Arsalan Arif and John Carroll on how the partnership held.
    Endpoints · 1mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 1mo ago↗ source